In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections

Bioorg Med Chem Lett. 2015 Feb 1;25(3):542-6. doi: 10.1016/j.bmcl.2014.12.029. Epub 2014 Dec 16.

Abstract

In this Letter, we presented in vitro studies of antimicrobial activity of Gly-His-Lys conjugates that are important point in preliminary biological evaluation of their potential application in skin and tissue therapies. The novel compounds include the conjugation of fatty acids with a modification of the amino acid sequence in the primary structure of Gly-His-Lys (6i). All the compounds exhibited strong to moderate activity. Compound 1d had the most potent antimicrobial activity at MIC ranges 31.3-125.0μg/mL (against Escherichia coli spp. and Staphylococcus aureus spp.), 375.0-500.0μg/mL (against Pseudomonas aeruginosa spp.). Conjugate 5b expressed activity against Staphylococcus aureus spp. and Escherichia coli spp. at MIC ranges 250.0-500.0μg/mL and 62.5-125.0μg/mL, respectively. Both conjugates 1d and 5b possessed rapid bactericidal activity against Gram-positive bacteria at 2MIC or 4MIC. Conjugates 1b-c, 1e, 2a-b and 4b showed noticeable effect against both Gram-positive and Gram-negative bacteria. Compounds 1d, 1e and 2e were the most active against fungus.

Keywords: Antimicrobial peptide; Fatty acid; Gly-His-Lys; Lipopeptide; Skin and tissue infections; Therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / chemical synthesis*
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Escherichia coli / drug effects
  • Fungi / drug effects
  • Humans
  • Microbial Sensitivity Tests
  • Oligopeptides / chemistry*
  • Pseudomonas aeruginosa / drug effects
  • Skin Diseases, Bacterial / drug therapy
  • Skin Diseases, Bacterial / microbiology
  • Staphylococcus aureus / drug effects

Substances

  • Anti-Infective Agents
  • Oligopeptides
  • glycyl-histidyl-lysine